Serplulimab Combined With CCRT for LS-SCLC.

Exclusion Criteria

• •1. Patients with extensive-stage small cell lung cancer
• •2. Cancer patients who have undergone surgery, radiotherapy, chemotherapy, or immunotherapy for small cell lung cancer
• •3. LS-SCLC patients with stage I disease amenable to surgical resection
• •4. Patients with active autoimmune diseases requiring systemic treatment (with disease-modifying agents, corticosteroids, or immunosuppressive drugs) within the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed
• •5. History of (non-infectious) pneumonia/interstitial lung disease requiring steroids or current active pneumonia/interstitial lung disease requiring steroids
• •6. Previously diagnosed with immunodeficiency diseases such as immunoglobulin deficiency, aplastic anemia, etc.
• •7. Known history of human immunodeficiency virus (HIV) infection
• •8. Concurrent active hepatitis B (defined as HBV DNA \> 500 copies) and hepatitis C virus (defined as HCV RNA (+)) infection
• •9. Known active tuberculosis history (tuberculin bacillus)
• •10. Receipt of live vaccine or attenuated live vaccine within 30 days prior to the first study intervention. Use of inactivated vaccines is allowed. Live vaccines include, but are not limited to: measles, mumps, rubella, varicella/zoster (chickenpox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccines. Injectable seasonal influenza vaccine is generally an inactivated virus vaccine and is allowed; however, intranasal influenza vaccine (e.g., FluMist®) is an attenuated live vaccine and is not allowed
• •11. Known other malignancy within the past 1 year that is progressing or requires active treatment. Note: Excludes adequately treated basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma (excluding in situ bladder carcinoma)
• •12. Symptomatic central nervous system metastases and/or carcinomatous meningitis
• •13. Severe hypersensitivity reaction (≥3 grade) to nivolumab/platinum/etoposide and/or any of their excipients
• •14. Active infection requiring systemic therapy
• •15. Any medical condition the investigator believes would pose excessive risk to the patient. For example, poorly controlled diabetes, active infection requiring parenteral anti-infective therapy, hepatic failure, any psychiatric condition that would interfere with understanding the informed consent form (ICF). Any past or present disease, treatment, laboratory abnormality, or other condition that, in the opinion of the investigator, would confound the study results or interfere with participation throughout the study
• •16. Known psychiatric illness or substance abuse that would interfere with compliance with trial requirements
• •17. Pregnancy, lactation, planned pregnancy, or intent to become pregnant or father children during the expected duration of the study (from screening visit through 180 days after the last dose of investigational drug)
• •18. Prior allogeneic tissue/organ transplantation
• •19. Patients unable to comply with study visits
• •20. Currently participating in or has used other investigational drugs or devices